Pulse Biosciences initiates research collaboration for thyroid cancers treatment

Pulse Biosciences (PLSE) announced a research collaboration with The University of Texas MD Anderson Cancer Center to examine the use of the company’s nPulse Vybrance Percutaneous Electrode System for treatment of thyroid cancers. The Investigational Device Exemption submitted for this first-in-human clinical feasibility study has been approved by the FDA. Under the agreement, MD Anderson researchers will conduct a clinical study to assess the safety and effectiveness of using nPulse technology to treat papillary thyroid microcarcinoma. The trial is planned to commence early in 2026. The study will be conducted at two sites and is planned to enroll 30 subjects. Under an existing material transfer agreement, preclinical studies with MD Anderson researchers are ongoing to assess the effect of nsPFA energy on anaplastic thyroid carcinoma. With a five-year survival rate of less than 5%, anaplastic thyroid carcinoma is one of the deadliest types of cancer.